Skip to content

Study · Randomized controlled trial · n = 87 · 2015

4 results

Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.

Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K

Journal of pain and symptom management14 Nov 2014Cited by 62 (Europe PMC)

PMID25462210 (opens in a new tab)DOI10.1016/j.jpainsymman.2014.09.013 (opens in a new tab)PepBankPUB-25462210
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In malignant bowel obstruction, mean vomiting-free days were 1.87 (SD 1.10) with octreotide versus 1.69 (SD 1.15) with placebo (P = 0.47).

    In plain wordsIn patients with malignant bowel obstruction, octreotide produced slightly more vomiting-free days than placebo, without a significant difference.

    Peptide
    Octreotide
    Outcome
    IncreaseDays free of vomiting
    Study

    n = 87

    Comparator
    placebo with the same standardized supportive therapy
    Analysis
    Primary
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    600 μg/24 hours · infusionAs given in this study (human).

    Measurements

    Vomiting-free days
    1.87 days
    octreotide
    SD
    1.1 days
    octreotide
    Vomiting-free days
    1.69 days
    placebo
    SD
    1.15 days
    placebo
    P
    0.47
    reported comparison

    Source sentences

    Summary
    Mean days free of vomiting were 1.87 (SD 1.10; octreotide) and 1.69 (SD 1.15; placebo; P = 0.47).
    5 context sentences
    Summary · context
    The primary outcome was patient-reported days free of vomiting at 72 hours.
    Summary · context
    Twelve services enrolled people with advanced cancer presenting with vomiting secondary to bowel obstruction where surgery or anti-cancer therapies were not indicated immediately.
    Summary · context
    In a double-blind study, participants were randomized to placebo or octreotide (600 μg/24 hours by infusion).
    Summary · context
    Both arms received standardized supportive therapy (infusion of ranitidine [200 mg/24 hours], dexamethasone [8 mg/24 hours], and parenteral hydration [10-20 mL/kg/24 hours]).
    Summary · context
    In a study that recruited to the numbers identified in its power calculation, 87 participants provided data at 72 hours (45, octreotide arm).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In malignant bowel obstruction, 17 octreotide and 14 placebo recipients were vomiting-free for 72 hours (P = 0.67).

    In plain wordsIn patients with malignant bowel obstruction, more octreotide than placebo recipients were vomiting-free for 72 hours, without a significant difference.

    Peptide
    Octreotide
    Outcome
    IncreaseVomiting-free for 72 hours
    Study

    n = 87

    Comparator
    placebo with the same standardized supportive therapy
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    600 μg/24 hours · infusionAs given in this study (human).

    Measurements

    Vomiting-free
    17 patients
    octreotide
    Vomiting-free
    14 patients
    placebo
    P
    0.67
    reported comparison

    Source sentences

    Summary
    Seventeen people (octreotide) and 14 (placebo) were free of vomiting for 72 hours (P = 0.67).
    4 context sentences
    Summary · context
    Twelve services enrolled people with advanced cancer presenting with vomiting secondary to bowel obstruction where surgery or anti-cancer therapies were not indicated immediately.
    Summary · context
    In a double-blind study, participants were randomized to placebo or octreotide (600 μg/24 hours by infusion).
    Summary · context
    Both arms received standardized supportive therapy (infusion of ranitidine [200 mg/24 hours], dexamethasone [8 mg/24 hours], and parenteral hydration [10-20 mL/kg/24 hours]).
    Summary · context
    In a study that recruited to the numbers identified in its power calculation, 87 participants provided data at 72 hours (45, octreotide arm).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In malignant bowel obstruction, adjusted vomiting incidence was lower with octreotide than placebo (incidence rate ratio 0.40; 95% CI 0.19-0.86; P = 0.019).

    In plain wordsIn patients with malignant bowel obstruction, adjusted vomiting incidence was lower with octreotide than placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseVomiting episodes
    Study

    n = 87

    Comparator
    placebo with the same standardized supportive therapy
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    600 μg/24 hours · infusionAs given in this study (human).

    Measurements

    Incidence rate ratio
    0.4
    reported comparison
    95% CI
    0.19 to 0.86
    reported comparison
    P
    0.019
    reported comparison

    Source sentences

    Summary
    An adjusted multivariate regression of the incidence of vomiting over the study showed a reduced number of episodes of vomiting in the octreotide group (incidence rate ratio = 0.40; 95% CI: 0.19-0.86; P = 0.019);
    4 context sentences
    Summary · context
    Twelve services enrolled people with advanced cancer presenting with vomiting secondary to bowel obstruction where surgery or anti-cancer therapies were not indicated immediately.
    Summary · context
    In a double-blind study, participants were randomized to placebo or octreotide (600 μg/24 hours by infusion).
    Summary · context
    Both arms received standardized supportive therapy (infusion of ranitidine [200 mg/24 hours], dexamethasone [8 mg/24 hours], and parenteral hydration [10-20 mL/kg/24 hours]).
    Summary · context
    In a study that recruited to the numbers identified in its power calculation, 87 participants provided data at 72 hours (45, octreotide arm).
  4. 04HumanRandomized controlled trialSafety outcome

    In malignant bowel obstruction, octreotide recipients were 2.02 times more likely to receive hyoscine butylbromide than placebo recipients (P = 0.004).

    In plain wordsIn patients with malignant bowel obstruction, octreotide recipients more often needed hyoscine butylbromide than placebo recipients, potentially reflecting increased colicky pain.

    Peptide
    Octreotide
    Outcome
    IncreaseHyoscine butylbromide use
    Study

    n = 87

    Comparator
    placebo with the same standardized supportive therapy
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    600 μg/24 hours · infusionAs given in this study (human).

    Measurements

    Relative likelihood
    2.02
    hyoscine butylbromide administration
    P
    0.004
    reported comparison

    Source sentences

    Summary
    however, people in the octreotide arm were 2.02 times more likely to be administered hyoscine butylbromide (P = 0.004), potentially reflecting increased colicky pain.
    4 context sentences
    Summary · context
    Twelve services enrolled people with advanced cancer presenting with vomiting secondary to bowel obstruction where surgery or anti-cancer therapies were not indicated immediately.
    Summary · context
    In a double-blind study, participants were randomized to placebo or octreotide (600 μg/24 hours by infusion).
    Summary · context
    Both arms received standardized supportive therapy (infusion of ranitidine [200 mg/24 hours], dexamethasone [8 mg/24 hours], and parenteral hydration [10-20 mL/kg/24 hours]).
    Summary · context
    In a study that recruited to the numbers identified in its power calculation, 87 participants provided data at 72 hours (45, octreotide arm).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.